Insight
Women’s mental health happens between appointments

By Ritika Sukhani – Psychologist, part of Véa’s Clinical Advisory Board
Women’s mental health often unfolds before, between and around appointments, long before it can be neatly explained in one conversation.
A woman arrives at a GP appointment with six months of feeling “off” behind her. Not acutely unwell. Not necessarily in crisis. Just not herself.
Poor sleep. Brain fog. Lower tolerance. Irritability before her period. Anxiety before meetings. A sense that her cycle, workload, relationships and energy are interacting – but not in a way she can neatly explain when the appointment begins.
She has tracked symptoms, Googled at midnight, screenshotted articles, made notes in her phone and tried to remember what changed, when it changed and what might have triggered it.
But when she finally gets the chance to talk, the task is not only to describe how she feels. It is to organise months of fluctuating experience into a story clear enough to communicate.
This is one of the most overlooked forms of labour in women’s mental health: not simply experiencing distress but having to make it coherent.
In the NHS, women’s mental health rarely arrives through one door. It may appear in primary care as exhaustion, poor sleep or “not feeling like myself”.
It may appear in NHS Talking Therapies as anxiety or low mood. It may sit beneath a menopause conversation, a fertility journey, chronic pain, trauma, caring responsibilities, burnout or the quiet work of holding everyone else together.
The NHS provides essential care.
NHS Talking Therapies received 1.81 million referrals in 2024/25, with 1.21 million referrals accessing services and 50.5 per cent of referrals moving to recovery after completing treatment.
But women’s lives do not unfold in pathway-shaped ways.
Their distress is often cumulative, contextual and relational. It is shaped not only by symptoms but by the conditions around those symptoms: work, debt, trauma, hormones, caregiving, discrimination, physical health, relationships, sleep and the pressure to keep functioning.
That is why women’s mental health needs more than access to services.
It needs continuity.
The work before the appointment
Women are often encouraged to advocate for themselves in healthcare. At its best, this is empowering. It supports agency, preparation and active participation in care.
But self-advocacy can also become another unpaid job.
It requires women to notice what is happening, remember when it started, connect it to context, decide what feels relevant, find the right words and communicate it clearly – often while already tired, anxious, in pain or emotionally overwhelmed.
In clinical care, distress is often the beginning of an assessment. Clinicians are trained to explore duration, severity, functioning, risk, context, history and meaning.
That process matters. It is how distress becomes understood with care.
The issue is broader than any single consultation.
Women’s mental health experiences often unfold over weeks, months and years, while healthcare conversations may happen in short, pressured windows.
Patterns form outside the appointment room: between cycle phases, work demands, caring responsibilities, relational stress, poor sleep and moments of emotional overload.
The UK Government’s Women’s Health Strategy survey found that 84 per cent of respondents said there had been times when they, or the woman they had in mind, were not listened to by healthcare professionals.
It points to something structural: the difficulty of making complex, fluctuating and context-dependent experiences legible inside systems that are often fragmented, time-limited and under pressure.
Endometriosis shows why continuity, language and recognition matter.
Research has found that delays in diagnosis can occur at both patient and medical levels, including when symptoms are normalised by women themselves and by doctors.
For many women, receiving a diagnosis did more than name pain; it provided language, reassurance and possible management strategies.
This is the point we should pay attention to.
Women do not always lack information. Often, they have fragments of it.
The challenge is how to preserve context, recognise recurrence and bring scattered experiences into a form that supports reflection, communication and earlier action.
Tracking captures moments. Continuity reveals patterns
We have made enormous progress in helping women track their bodies.
We can now log cycles, sleep, mood, fertility windows, temperature, symptoms, recovery and heart rate variability with increasing precision. Period-tracking apps, for example, have been described as tools that can support body awareness and menstrual health literacy, while also introducing new forms of work, distress and privacy concern for some users.
That tension matters.
Tracking can help women notice what is happening. But noticing is not the same as understanding. And understanding is not the same as being able to explain.
A cycle tracker can show when a period started. A wearable can show disrupted sleep. A symptom log can hold isolated data points. A notes app can capture fragments of a difficult week.
But unless those pieces are brought together, the interpretive work still falls to the woman.
She is left asking: Is this hormonal? Is this stress? Is this burnout? Is this anxiety? Is this normal for me? Is this pattern important? Should I mention it? How do I explain it?
This is where the first wave begins to meet its limits.
The first wave helped women capture signals.
The next wave could help women interpret context.
The promise of patient-generated health data has always been that it could bridge the gap between everyday life and formal care. But reviews continue to highlight challenges around integration with electronic health records, trust, provenance, data quality and contextual information.
That matters because women’s health data does not become useful simply because it is collected. It becomes useful when it is contextualised.
A poor night’s sleep means something different after one stressful day than after six weeks of overextension.
A low mood entry means something different when it appears in isolation than when it appears repeatedly around a cycle phase, a work pattern or a relationship dynamic.
A spike in anxiety means something different when it is viewed alongside workload, recovery, conflict, hormonal change or self-critical thinking.
The value is not in turning every experience into a metric.
The value is in seeing what repeats, how it repeats and what else is happening around it.
Women’s mental health is systemic
The latest Adult Psychiatric Morbidity Survey found that one in five adults in England had a common mental health condition, with prevalence higher in women at 24.2 per cent compared with 15.4 per cent in men.
It also found a clear socioeconomic gradient, with common mental health conditions more prevalent in the most deprived areas and among people with problem debt.
These figures matter because they remind us that women’s mental health cannot be understood only at the level of individual coping.
Of course, individual support matters. Therapy matters. Medication may matter. Assessment, formulation, risk management and diagnosis all have their place.
But a systemic lens asks what else is happening around the woman.
Who is she caring for? What is she carrying at work? What has she had to normalise? What physical symptoms have been separated from her emotional life? What inequalities shape how quickly she is heard, referred or supported? What happens while she is waiting?
Women’s mental health is often partly biological, partly psychological, partly relational, partly occupational and partly social.
It may not fit neatly into one symptom box at first. It may need time, pattern and context before it becomes clear what kind of support is needed.
This is why the missing layer is not more monitoring – it is supported sense-making.
The need for supported sense-making
Supported sense-making means moving beyond isolated logs and dashboards towards tools that help women understand how different parts of their lives interact over time: body, mood, cycle, stress, relationships, work, recovery and self-talk.
It also means being clear about what technology should and should not do.
Technology should not replace clinical assessment. It should not diagnose from a journal entry.
It should not turn ordinary emotion into pathology or place yet another responsibility on women to optimise themselves.
At its best, it can support the wider ecosystem around care.
It can help women hold onto context before an appointment.
It can help them notice patterns while they are waiting. It can support reflection between sessions. It can help them arrive at conversations with more continuity, while respecting the clinical judgement, formulation and relational care that services provide.
This is where platforms like Véa point toward a thoughtful role for women’s health technology.
By treating reflection, emotion and language as part of women’s longitudinal health context, Véa supports the kind of pattern recognition that often gets lost in daily life. Through micro-check-ins, journalling and reflective prompts, it helps women notice shifts in their internal state over time – not to self-diagnose but to build a clearer relationship with their own patterns.
For some women, that may support a better conversation with a clinician.
For others, it may help them recognise early signs of burnout, understand cyclical changes or notice when work, relationships and recovery are interacting in ways they had not previously named.
At its best, this kind of technology reduced the burden of self-interpretation. It helps women hold onto the thread.
From more data to better continuity
The women’s health gap is often discussed as a research gap, a funding gap and a diagnostic gap.
It is all of those things. McKinsey Health Institute and the World Economic Forum estimate that closing the women’s health gap could add at least $1 trillion annually to the global economy by 2040.6
But there is another gap sitting underneath the others.
A continuity gap.
Women’s mental health experiences are often long, fluctuating and context-dependent. Healthcare systems often encounter them in snapshots. Workplaces may only notice them when performance drops. Women themselves may only recognise the pattern once they are already exhausted.
That gap between lived experience and later explanation is where too much meaning gets lost.
The next generation of women’s health technology should help preserve the story behind the symptom.
It should make room for emotional, cognitive, hormonal and social context without collapsing everything into diagnosis or optimisation. It should support better conversations without pretending to replace clinical care.
Women should not have to rely on memory alone to make sense of months of fluctuating emotional, cognitive and physical experience.
The future of women’s mental health will not be built by asking women to monitor themselves more closely.
It will be built by helping them understand themselves sooner – and arrive at conversations about their health with more continuity, context and clarity.
Learn more about Véa at veajournal.app
Insight
From Hologic to Ark Surgical: Why Joseph LaBruzzo is betting on the future of women’s surgical innovation

After more than two decades leading organisations at some of the world’s most respected medical device companies, including Hologic, SenoRx Breast Care, and BTL Industries, Joseph B. LaBruzzo is embarking on a new chapter as President & CEO of U.S. Operations and Board Member at Ark Surgical.
We sat down with Joseph to discuss what drew him to Ark Surgical, why he believes women’s surgical innovation is entering a transformative era, and what it takes to bring meaningful technologies from concept to standard of care.
You have held leadership positions at some of the biggest names in MedTech. What attracted you to Ark Surgical?
Throughout my career, I’ve been fortunate to work with organisations that developed technologies capable of changing the standard of care.
What attracted me to Ark Surgical is the opportunity to help address a meaningful unmet need in gynecologic surgery with an innovation that has the potential to improve patient outcomes while preserving the benefits of minimally invasive surgery.
Opportunities like that don’t come along very often.
FemTech World recently highlighted that many women remain unaware of gynecologic cancers and that unexpected diagnoses continue to have a profound impact on patients and families.
How has your own experience shaped the way you think about innovation in women’s health?
Earlier in my career, I witnessed many women receive life-changing cancer diagnoses.
Those experiences stayed with me and reinforced my belief that if there’s an opportunity to reduce risk through better innovation, it’s one worth pursuing.
That’s one of the reasons I was drawn to Ark Surgical.
The vast majority of minimally invasive gynecologic procedures are performed for conditions believed to be benign. Unfortunately, in rare cases, pathology later reveals an unexpected malignancy.
LapBox was designed with a proprietary dual-wall tissue containment system to help facilitate contained specimen retrieval and minimise the risk of tissue spillage during laparoscopic procedures.
I believe innovations like this can help surgeons manage the unexpected while preserving the many benefits of minimally invasive surgery for women.
Women’s health has gained significant momentum in recent years, yet surgical innovation often receives less attention than diagnostics or therapeutics. Why do you think that is?
Women’s health has historically been underfunded and underserved across many areas of medicine, and surgery is no exception.
While we’ve seen tremendous advances in diagnostics and pharmaceuticals, there are still important opportunities to improve the surgical experience for both physicians and patients.
Innovation that enhances safety, efficiency, and outcomes has the potential to make a lasting impact.
What excites you most about LapBox?
LapBox addresses a very real challenge that gynecologic surgeons face during minimally invasive procedures.
It was thoughtfully designed to integrate seamlessly into the surgical workflow while providing an added layer of confidence when tissue retrieval is required.
I believe technologies that solve real clinical challenges in a practical way have the greatest potential to become part of the standard of care.
What do you see as the biggest unmet needs in minimally invasive gynecologic surgery today?
The future of surgery isn’t simply about making procedures less invasive. It’s about making them smarter and safer.
Surgeons need technologies that integrate seamlessly into their workflow while helping them navigate increasingly complex clinical situations.
Every advancement that helps reduce risk while preserving the benefits of minimally invasive surgery has the potential to improve outcomes for both physicians and patients.
That’s where I believe the greatest opportunities for innovation exist.
As you take on this new role, what are your priorities over the next 12 months?
Our focus over the next 12 months is to build a strong foundation for growth. That means expanding physician partnerships, driving early clinical adoption, growing our team, and ensuring that more surgeons have access to technologies like LapBox.
At the same time, we’re focused on building strategic relationships with investors, healthcare systems, and industry partners that support our long-term vision.
What advice would you give entrepreneurs building the next generation of women’s health companies?
Start with a real clinical problem and never lose sight of the patient.
Great technology alone isn’t enough. You also need strong clinical evidence, physician advocates, and a clear market strategy. The companies that succeed are the ones that bring all of those pieces together while remaining focused on improving patient care.
About Joseph B. LaBruzzo
As President & CEO of U.S. Operations and Board Member, Joseph LaBruzzo is leading Ark Surgical’s U.S. growth strategy, physician partnerships, strategic investment initiatives, and organisational expansion, supporting the company’s mission to advance safer minimally invasive gynecologic surgery through innovative technologies.
Insight
Cancer cells secretly hijacking fertility protein to survive chemo, research finds

Cancer cells may hijack a fertility protein to repair damaged DNA and survive chemotherapy, research suggests.
The findings could point to a way of making existing cancer treatments more effective.
SYCP1 is a protein normally involved in producing sperm and eggs.
Researchers at the University of Liverpool found that the protein, previously thought to work only in reproduction, can be reactivated in cancer cells, where it helps tumours survive and grow.
SYCP1 usually helps chromosomes pair during meiosis, the form of cell division that produces reproductive cells.
In cancer cells, however, the protein appears to take on another role. It enters the nucleus, the cell’s control centre, binds directly to DNA and regulates genes involved in cell division and DNA repair.
DNA repair is how cells fix damage to their genetic code. In cancer, this process can help tumour cells survive treatment.
The researchers found that removing SYCP1 made cancer cells much more sensitive to chemotherapy drugs that damage DNA.
The findings suggest cancers may use SYCP1 to repair damage caused by treatment and continue growing.
Dr Urszula McClurg, lecturer in biochemistry, cell and systems biology at the University of Liverpool, said: “Our findings show that cancer cells can hijack proteins that normally exist only in reproductive tissues and give them completely new jobs.
“Understanding these unexpected functions opens up exciting opportunities to develop new treatments that make existing cancer therapies more effective.”
The work challenges the long-held belief that proteins active only in fertility have no biological relevance outside the reproductive system.
Researchers say these specialised proteins could provide new treatment targets across many types of cancer.
The study also offers a new view of how cancers evolve by repurposing developmental and reproductive processes.
The findings highlight SYCP1 as a candidate for future precision cancer therapies, which are treatments based on the specific biology of a patient’s cancer.
News
What “women’s healthmaxxing” means for patient trust and the femtech industry

Women’s health has become one of the most searched and shared topics online, from cycle syncing and cortisol management to menopause hacks, supplements, hormone testing and clinician-creator content.
That surge in attention, sometimes dubbed “healthmaxxing,” is changing how women find, evaluate and act on health information, and it is starting to reshape the relationship between patients, clinicians and the companies building products for this market.
For providers, the shift means patients are arriving better informed but also more exposed to unverified claims, putting pressure on clinicians to engage with online narratives rather than dismiss them.
For femtech and pharma companies, it opens a route to reach and educate consumers at scale, but also raises the stakes on credibility: products and messaging that ride the trend without clinical grounding risk eroding the trust the industry has spent years building.
Investors are watching the same dynamic from a different angle.
Attention-driven demand can be a signal of where the next wave of femtech growth will come from, but distinguishing genuine clinical need from viral momentum is increasingly part of due diligence.
The net effect is a widening gap between companies that treat cultural attention as a distribution channel for credible, evidence-based care, and those that risk being swept up in trends with little clinical substance behind them.
How that gap plays out will shape patient trust, clinical relationships and commercial opportunity across the women’s health industry for years to come.
These themes will be explored in more depth in an upcoming webinar, “Women’s Healthmaxxing: The Opportunity & Risks of Cultural Attention for the Women’s Health Industry,” hosted by the Women’s Health Innovation Summit (WHIS), featuring Ellen Wilcox (Listen Ventures), Jessica Bell van der Wal (Frame Fertility), Dr. Tosin Sotubo-Ajayi (NHS, BBC and more) and Nora Lansen (Elektra Health).
Register free for the webinar on 23 July 2026 at https://events.virtualpro.com/womens-health-series-webinar-july-2026/registration
News1 week agoNew menopause drug approved for use by NHS in Scotland
Hormonal health1 week agoStardust period tracker shares health data, study reveals
News3 days agoZero Candida market set to reach over US$2 billion by 2030 – report
Insight1 week agoWomen’s health draws record $1.55bn in equity as capital spreads beyond the mega-rounds
Mental health2 weeks agoSSRIs may lower heat intolerance in women with depression – study
News2 weeks agoAvni Wellness secures US$470k funding
Insight2 weeks agoSoftening ovaries could extend fertility as women age, study suggests
Entrepreneur1 week agoOnto Health acquires diagnostics software company Levy Health












